PHAS PhaseBio Pharmaceuticals Inc.

10.64
+0.02  (+0%)
Previous Close 10.62
Open 10.66
Price To Book 6.91
Market Cap 304590748
Shares 28,626,950
Volume 179,833
Short Ratio
Av. Daily Volume 649,085

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2020.
PB1046
Pulmonary arterial hypertension (PAH)
Phase 2a initial data due 2Q 2019.
PB2452
Reversal agent for ticagrelor

Latest News

  1. PhaseBio Reports First Quarter 2019 Financial Results and Recent Corporate Progress
  2. PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019
  3. 2 Ultra-High Growth Stocks to Buy Now
  4. PhaseBio completes $49.5M stock sale
  5. PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  6. Billionaires Are Betting This Could Be One Of The Biggest Industries In History
  7. PhaseBio plans $43M stock sale
  8. PhaseBio Announces Pricing of Public Offering of Common Stock
  9. The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering
  10. PhaseBio Announces Proposed Public Offering of Common Stock
  11. Why PhaseBio's stock rose 16 percent Tuesday
  12. Here's Why PhaseBio Pharmaceuticals Rose as Much as 32.5% Today
  13. PhaseBio Stock Up on Breakthrough Therapy Status for PB2452
  14. The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing
  15. PhaseBio shares soar 28% premarket as FDA speeds path for approval of PB2452
  16. Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News
  17. PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
  18. 3 Stocks That Have More Than Tripled So Far in 2019
  19. PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results
  20. The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs